China’s research and development industry has recently been flourishing with support from the government’s newer policies and increasing investment
China Cell Therapy Market Opportunity & Clinical Trials Insight 2028 Report Highlights:
- More Than 400 Cell Therapies Are In Clinical Trials In China
- 2 Cell Therapies Are Commercially Approved
- Insight on More Than 25 Cell Therapies Proprietary Technologies Developed By Chines Companies
- China Cell Therapy Market Opportunity Assessment
- Insight On More Than 400 Cell Therapies In Clinical Trials By Phase, Indication, Company
- Analysis On Pricing & Reimbursement Framework
- Insight On Key Chinese Pharmaceutical Companies Involved In R&D OF Cell Therapies
Download Report: https://www.kuickresearch.com/report-china-cell-therapy-market
China’s research and development industry has recently been flourishing with support from the government’s newer policies and increasing investment. Being the disease with the highest mortality rate, cancer has emerged as the largest therapeutic sector in China’s R&D sector. The incidences of cancer that were previously more common in the US have been slowly increasing in China which has been attributed to the population slowly starting to lean towards the unhealthy westerns lifestyle. This has prompted researchers to find new and more effective cancer treatment methods, as a result of which, immunotherapy slowly came into picture. Out of all the immunotherapies, cell therapy has been getting the most attention in recent times.
China was among the first countries to dive into the cell and gene therapy R&D, consequently becoming the first country to have a gene therapy approved. Even with several ongoing clinical trials, its entry in the international cell therapy market was relatively slow. The country approved its first cell therapy in the year 2021, which was followed by another cell therapy approval a couple of months later in the same year. Being the first cell therapies approved in China, it was a groundbreaking feat for China’s pharmaceutical market which brought hope for many patients unresponsive to conventional therapy methods.
The history of cell therapy in China is not very old; the country’s first cell therapy results were published in 2013 about a trial conducted on cancer patients. Owing to the easy availability of patients for clinical studies, China has become a popular destination for conducting trials after the US, with several medical centers, hospital and medical universities conducting trials on willing patients after getting permission from the health ministry. Presently, only selected major hospitals have been given this privilege which helps in early evaluation of drugs in patients before further development.
As is evident from the clinical trials studies, cancer is the most the popular indication for a large proportion of the cell therapies under development, which can be attributed to the large number of cancer patients in the region and the demand thus generated for their treatment. Cell therapy has helped in the treatment of cancer patients who were previously unresponsive to the conventional cancer treatment methods.
Out of the four common cell therapy methods, chimeric antigen receptor (CAR) cells have gained the most recognition which can also be seen in China’s market with the two approved therapies being CAR – T therapies. Apart from T cell directed towards various cellular antigens, NK cell are also being evaluated in clinical trials; however their count is lower than that of T cells. This number is expected to rise in the coming years as research increases in the CAR – NK therapeutic segment. In clinical studies, CAR – NK have demonstrated far better results than CAR – T cells, which has been slowly directing researchers’ attention towards this new cell therapy method which may provide a better alternative to CAR – T therapies.
With multiple international companies collaborating with local Chinese countries to have their cell therapies in the domestic market, many partnerships are now emerging with major global pharma companies like Merck and Janssen taking the lead. This has also been fueled with the central government’s favorable policies which provide incentives to pharma companies. The government has also set up industrial zones in several metropolitan cities which have been attracting foreign companies for setting up their business units in the region, thus boosting their economy and helping domestic companies with their expertise.
As the prevalence of cancer grows in the region, more companies are expected to turn towards the development of cell therapies. This comes from the commercial success of multiple cell therapies in the international market which gives hope from China’s market as well. With technological advancements in the region and those brought in by international companies, the cell therapy market is expected to grow further and more therapies are expected to be approved in the coming years.
Contact:
Neeraj Chawla
Kuick Research
Research Head